Dominion Resources, Inc. (NYSE:D) released that its fourth quarter earnings of $0.84 a share, excluding non-recurring items. The firm released that its $0.01 improved than the Capital IQ Consensus Estimate of $0.83. The chairman, president and CEO, Thomas F. Farrell II stated that 2014 was a year of important accomplishments for Dominion as they completed several main capital projects and made significant progress to advance the after that round of infrastructure growth. Apart from five cents per share impact of mild weather, full year operating earnings were in the middle of their outlook range. Whereas, shares of Dominion Resources, Inc. (NYSE:D) traded down of -3.79% to finished at USD75.71 with market capitalization of 44.47 billion. Separately, a research note to investors, 10 analysts rates its stocks at “Hold,” 4 analysts rate it at “strong buy” and 7 rate it a “Buy.”
Cablevision Systems Corporation (NYSE:CVC) reported that the firm’s president Brian Sweeney will as well become CFO, effective March 1, 2015. Sweeney be successful Gregg Seibert who will persist to serve as vice chairman of Cablevision, working on the company’s long-term strategic and financial initiatives. Share price of Cablevision Systems Corporation (NYSE:CVC) fell -1.10% to closed at $19.77 with the traded volume of 2.01 million shares as compared to the average volume of 2.90 million in last session. The 12 analysts rate its stocks at “Hold,” 3 analysts rate it at “strong buy” and 2 rate it a “Buy,” according to a recent a pool of analysts rating.
GlaxoSmithKline plc (ADR) (NYSE:GSK) released that in general survival or OS results from COMBI-d which demonstrate a statistically important reduction in the risk of death for the combination of dabrafenib as well as trametinib compared dabrafenib monotherapy in patients by means of BRAF V600E/K mutation-positive metastatic melanoma. The safety profile was reliable by means of the profile observed to date for the combination; no new safety concerns were observed. As, GlaxoSmithKline plc (ADR) (NYSE:GSK) has 0.60 beta factor with last traded share price of $46.00 with positive change of 0.11%. On analytic notes; diverse intension of analysts reflects as, 2 analysts rates its stocks at “Hold,” 1 analyst rate it at “strong buy” and 1 rate it a “Underperform.”
Harris Corporation (NYSE:HRS) has decided to purchased Exelis Inc. (XLS) in a cash and stock contract worth at $23.75 a share, or around $4.75B enterprise value. Pursuant to the transaction, Exelis shareholders would get $16.625 in cash as well as 0.1025 of per share of Harris common stock, based on Harris’ closing price as of February 5, 2015, for a share of Exelis common stock. Upon completion, Harris shareholders would own around 85% of the combined company, and Exelis shareholders would own about 15%. Harris Corporation (NYSE:HRS) stock surged of 9.63% to closed at $76.18 with the total traded volume of 7.25 million shares. The consensus average revenue estimates are $1.18B for latest quarter, at the same time as 7 experts predict $1.23B revenues for the next three months of 2014.